ArticleGenome medicine2026
Recombination and accessory genome turnover shaped the rise and decline of vanA Enterococcus faecium ST80 in Denmark.
Article in Genome medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
Abstract
backgroundVancomycin-resistant Enterococcus faecium (VREfm) is a major cause of hospital-associated infections globally. In the Capital Region of Denmark, VREfm ST80 emerged as the dominant vanA-positive clone but declined significantly over the following decade.
methodsTo investigate the genomic mechanisms underlying this epidemiological shift, we assembled and performed whole-genome sequencing and phylogenomic analysis of 334 ST80 isolates collected from colonisation (83%) and infection (17%) cases across nine hospitals in the region between 2012 and 2020.
resultsTwo major clusters (Clusters 1 and 2) and nine sub-clusters (1.A-G and 2.H-I) were identified. Sub-cluster-1.A (169/334) was the dominant lineage, accounting for 72% of isolates from 2012-2015. Isolates from 2016-2020 were distributed across all sub-clusters, indicating increasing diversification over time. Genetic variation was driven by accumulation of mutations, recombination and gain/loss of accessory genes and plasmids. Eight recombination hotspots were identified in core genes involved in cell wall synthesis, phosphotransferase systems, amino-acid biosynthesis, and several transporters. Accessory genome comparisons revealed sub-cluster-specific enrichment of resistance genes, including ermG (89% in 1.B), tet(S) (85% in 1.A), and tet(M) (88% in sub-cluster-1.B). Additionally, genes associated with biofilm formation, ABC transporters, and biosynthesis of polysaccharides, terpenoids, and aspartate were differentially enriched across the clusters. These genomic signatures may have contributed to niche adaptation and intra-clonal diversification. Plasmidome analysis showed increased diversity in later years, with the decline of Inc18 family plasmids (from 80 to 38%) and the rise of two new plasmids, coinciding with reduced clonal stability. Long-read hybrid assemblies uncovered mosaic phage-like plasmids harboring the vanA operon alongside ermB, aadE, and aph(3')-IIIa suggesting a unique mechanism for co-mobilization of antimicrobial resistance via transduction or conjugation. Despite the observed diversity, a continuous and sustained intra- and inter-hospital transmission and dissemination of this clone was evidenced by the small SNP difference (≤ 15 SNPs) between strains.
conclusionsThis study showed the continuous hospital transmission and intra-clonal diversity of VREfm ST80. The dissemination, transmission and persistence dynamics of the vanA ST80 clone in Denmark may have been shaped by recombination events and gain/loss of genes involved in general metabolism, antibiotic resistance and virulence, and inter-clonal competition.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.